Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical biopharmaceutical company, today announced plans to strategically expand into cryptocurrency and blockchain. The company plans to establish a subsidiary called American BNB Strategy to lead its digital asset investment and management program. Through this platform, Liminatus plans to raise and deploy up to $500 million in funding in phases with the goal of making a strategic long-term investment in BNB.
7月28日消息,临床前阶段生物制药公司 Liminatus Pharma, Inc.(纳斯达克股票代码:LIMN)今日宣布,计划战略性拓展至加密货币和区块链领域。公司拟成立名为「American BNB Strategy」(美国 BNB 策略)的子公司,主导其数字资产投资与管理计划。通过这一平台,Liminatus 计划分阶段筹集并部署高达 5 亿美元资金,目标是对 BNB 进行战略性长期投资。